Literature DB >> 30472734

Diet-induced insulin resistance elevates hippocampal glutamate as well as VGLUT1 and GFAP expression in AβPP/PS1 mice.

Erin R Hascup1,2, Sarah O Broderick1, Mary K Russell3, Yimin Fang4, Andrzej Bartke4, Heather A Boger3, Kevin N Hascup1.   

Abstract

The symptomologies of Alzheimer's disease (AD) develop over decades suggesting modifiable lifestyle factors may contribute to disease pathogenesis. In humans, hyperinsulinemia associated with type 2 diabetes mellitus increases the risk for developing AD and both diseases share similar age-related etiologies including amyloidogenesis. Since we have demonstrated that soluble Aβ42 elicits glutamate release, we wanted to understand how diet-induced insulin resistance alters hippocampal glutamate dynamics, which are important for memory formation and consolidation. Eight to twelve-week-old C57BL/6J and AβPP/PS1 mice were placed on either a low-fat diet or high-fat diet (HFD) for 8 months. A HFD led to significant weight increases as well as impaired insulin sensitivity, glucose tolerance, and learning in both C57BL/6J and AβPP/PS1 mice. AβPP/PS1 low-fat diet mice had elevated hippocampal basal as well as stimulus-evoked glutamate release that was further increased with consumption of a HFD. Immunohistochemistry indicated an increase in vesicular glutamate transporter 1 and glial fibrillary acidic protein density in hippocampal subregions corresponding with this elevated extracellular glutamate. While no differences in hippocampal plaque load were observed, the elevated astrogliotic response surrounding the plaques in AβPP/PS1 HFD mice may have been a compensatory mechanism to control plaque accumulation. These data support that AβPP/PS1 mice have chronically elevated extracellular glutamate that is exacerbated by a HFD and that modifiable lifestyle factors such as obesity-induced insulin resistance can contribute to AD pathogenesis. OPEN SCIENCE BADGES: This article has received a badge for *Open Materials* and for *Open Data* because it made the data publicly available. The data can be accessed at https://osf.io/5whvu (figures for data) and https://osf.io/gd5vf (materials and methods). The complete Open Science Disclosure form for this article can be found at the end of the article. More information about the Open Practices badges can be found at https://cos.io/our-services/open-science-badges/. Cover Image for this issue: doi: 10.1111/jnc.14490.
© 2018 International Society for Neurochemistry.

Entities:  

Keywords:  Alzheimer's disease; amyloid-beta; astrogliosis; cognition; diabetes; excitotoxicity

Mesh:

Substances:

Year:  2019        PMID: 30472734      PMCID: PMC6438176          DOI: 10.1111/jnc.14634

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  76 in total

1.  Ceramic-based multisite microelectrodes for electrochemical recordings.

Authors:  J J Burmeister; K Moxon; G A Gerhardt
Journal:  Anal Chem       Date:  2000-01-01       Impact factor: 6.986

Review 2.  Glutamate receptor function in learning and memory.

Authors:  Gernot Riedel; Bettina Platt; Jacques Micheau
Journal:  Behav Brain Res       Date:  2003-03-18       Impact factor: 3.332

3.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Ronald C Petersen; Michael W Weiner; Paul S Aisen; Leslie M Shaw; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Vernon S Pankratz; Michael C Donohue; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2013-02       Impact factor: 44.182

4.  Increased vesicular glutamate transporter expression causes excitotoxic neurodegeneration.

Authors:  Richard W Daniels; Bradley R Miller; Aaron DiAntonio
Journal:  Neurobiol Dis       Date:  2010-10-14       Impact factor: 5.996

5.  Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice.

Authors:  Andrew W Kraft; Xiaoyan Hu; Hyejin Yoon; Ping Yan; Qingli Xiao; Yan Wang; So Chon Gil; Jennifer Brown; Ulrika Wilhelmsson; Jessica L Restivo; John R Cirrito; David M Holtzman; Jungsu Kim; Milos Pekny; Jin-Moo Lee
Journal:  FASEB J       Date:  2012-10-04       Impact factor: 5.191

6.  Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice.

Authors:  Jennifer Alamed; Donna M Wilcock; David M Diamond; Marcia N Gordon; Dave Morgan
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

7.  Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function.

Authors:  Zoe Arvanitakis; Robert S Wilson; Julia L Bienias; Denis A Evans; David A Bennett
Journal:  Arch Neurol       Date:  2004-05

8.  Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice.

Authors:  George M Alley; Jason A Bailey; Demao Chen; Balmiki Ray; Lakshman K Puli; Heikki Tanila; Pradeep K Banerjee; Debomoy K Lahiri
Journal:  J Neurosci Res       Date:  2010-01       Impact factor: 4.164

9.  Alzheimer's disease drug-development pipeline: few candidates, frequent failures.

Authors:  Jeffrey L Cummings; Travis Morstorf; Kate Zhong
Journal:  Alzheimers Res Ther       Date:  2014-07-03       Impact factor: 6.982

Review 10.  The role of glutamate transporters in glutamate homeostasis in the brain.

Authors:  M Takahashi; B Billups; D Rossi; M Sarantis; M Hamann; D Attwell
Journal:  J Exp Biol       Date:  1997-01       Impact factor: 3.312

View more
  19 in total

Review 1.  Insulin resistance and impaired lipid metabolism as a potential link between diabetes and Alzheimer's disease.

Authors:  Joshua A Kulas; Thaddeus K Weigel; Heather A Ferris
Journal:  Drug Dev Res       Date:  2020-02-05       Impact factor: 4.360

2.  PhIP exposure in rodents produces neuropathology potentially relevant to Alzheimer's disease.

Authors:  Tauqeerunnisa Syeda; Rachel M Foguth; Emily Llewellyn; Jason R Cannon
Journal:  Toxicology       Date:  2020-03-10       Impact factor: 4.221

3.  LY379268 Does Not Have Long-Term Procognitive Effects nor Attenuate Glutamatergic Signaling in AβPP/PS1 Mice.

Authors:  Kevin N Hascup; Jesse Britz; Caleigh A Findley; Shelley Tischkau; Erin R Hascup
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

4.  Assessing Sex-Specific Circadian, Metabolic, and Cognitive Phenotypes in the AβPP/PS1 and APPNL-F/NL-F Models of Alzheimer's Disease.

Authors:  Jesse Britz; Emmanuel Ojo; Asmita Dhukhwa; Takashi Saito; Takaomi C Saido; Erin R Hascup; Kevin N Hascup; Shelley A Tischkau
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.472

Review 5.  Friend or Foe? Defining the Role of Glutamate in Aging and Alzheimer's Disease.

Authors:  MaKayla F Cox; Erin R Hascup; Andrzej Bartke; Kevin N Hascup
Journal:  Front Aging       Date:  2022-06-16

Review 6.  The Role of Mesenchymal Stem Cells in Regulating Astrocytes-Related Synapse Dysfunction in Early Alzheimer's Disease.

Authors:  Cong Liu
Journal:  Front Neurosci       Date:  2022-06-21       Impact factor: 5.152

7.  Amyloid Beta-Related Alterations to Glutamate Signaling Dynamics During Alzheimer's Disease Progression.

Authors:  Caleigh A Findley; Andrzej Bartke; Kevin N Hascup; Erin R Hascup
Journal:  ASN Neuro       Date:  2019 Jan-Dec       Impact factor: 4.146

8.  Studies of pathology and pharmacology of diabetic encephalopathy with KK-Ay mouse model.

Authors:  Si Shi; Hua-Jing Yin; Jiang Li; Ling Wang; Wei-Ping Wang; Xiao-Liang Wang
Journal:  CNS Neurosci Ther       Date:  2019-08-11       Impact factor: 5.243

Review 9.  Neurodegeneration in type 2 diabetes: Alzheimer's as a case study.

Authors:  Jalaja Madhusudhanan; Gowthaman Suresh; Vasudharani Devanathan
Journal:  Brain Behav       Date:  2020-03-14       Impact factor: 2.708

10.  Riluzole attenuates glutamatergic tone and cognitive decline in AβPP/PS1 mice.

Authors:  Kevin N Hascup; Caleigh A Findley; Jesse Britz; Nahayo Esperant-Hilaire; Sarah O Broderick; Kristin Delfino; Shelley Tischkau; Andrzej Bartke; Erin R Hascup
Journal:  J Neurochem       Date:  2020-11-17       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.